دورية أكاديمية
Risk factors for cataract in retinoblastoma management
العنوان: | Risk factors for cataract in retinoblastoma management |
---|---|
المؤلفون: | Jia, Shichong, Wen, Xuyang, Yu, Jie, Zhou, Min, Yang, Ludi, Feng, Yiyi, He, Xiaoyu, Jia, Renbing, Fan, Jiayan, Fan, Xianqun |
بيانات النشر: | BMJ Publishing Group Ltd |
سنة النشر: | 2024 |
المجموعة: | HighWire Press (Stanford University) |
مصطلحات موضوعية: | Ocular oncology |
الوصف: | Aims To investigate the risk factors for cataract following eye-preserving therapies for retinoblastoma. Methods This retrospective, single-centre cohort study included patients diagnosed with retinoblastoma receiving eye-preserving therapies between January 2017 and June 2021. Cataract by the end of the follow-up was the main outcome. Results Cataract was found in 31 of 184 (16.8%) included eyes during a mean follow-up of 27.6 months. The cataract and control groups were similar regarding patients’ laterality, sex and disease stage. Eyes in the cataract group were more likely to present with endophytic retinoblastoma (p=0.02) and greater intraocular pressure (p=0.001). Competing risk regression analysis (univariate Fine-Gray model) showed that the growth pattern (p=0.01), intraocular pressure (p=0.01), number of intra-arterial chemotherapy (IAC) cycles (p=0.001), melphalan dose per IAC cycle (p=0.001) and number of intravitreous chemotherapy (IvitC) cycles (p=0.001) were associated with cataract occurrence. Multivariate analysis included higher intraocular pressure (p=0.003), a higher melphalan dose per IAC cycle (p=0.001) and an increasing number of IvitC cycles (p=0.04) as independent risk factors for cataract. Conclusions Repeated IAC and/or IvitC with melphalan were the most common eye-preserving therapies that induced cataract formation. The toxic effect of melphalan was an essential factor in cataract development, as indicated by the association of cataract occurrence with the melphalan dose. |
نوع الوثيقة: | text |
وصف الملف: | text/html |
اللغة: | English |
العلاقة: | http://bjo.bmj.com/cgi/content/short/108/4/571Test; http://dx.doi.org/10.1136/bjo-2022-321723Test |
DOI: | 10.1136/bjo-2022-321723 |
الإتاحة: | https://doi.org/10.1136/bjo-2022-321723Test http://bjo.bmj.com/cgi/content/short/108/4/571Test |
حقوق: | Copyright (C) 2024, BMJ Publishing Group Ltd |
رقم الانضمام: | edsbas.DC8D54BA |
قاعدة البيانات: | BASE |
DOI: | 10.1136/bjo-2022-321723 |
---|